Genome&Company Acquires US ListLab... Enters CDMO Business

[Asia Economy Reporter Moon Hyewon] Genome&Company announced on the 8th that it has acquired List Biological Laboratory, a U.S. microbiome pharmaceutical contract development and manufacturing organization (CDMO) company.

Starting with the acquisition of management rights, it plans to enter the CDMO business.

Genome&Company will be able to improve the efficiency of producing microbiome new drug candidates that were previously under development while maintaining the independent operation of List Labs.

The strategy is to internalize microbiome pipeline production to stably operate clinical development.

It is also expected to generate revenue through the microbiome CDMO business.

List Biological Laboratory is a microbiome CDMO company with 43 years of history. It undertakes contract manufacturing of microbiomes and biotoxins. It possesses quality control capabilities that comply with the advanced countries' current Good Manufacturing Practice (cGMP) standards.

Jae-Soo Bae, CEO of Genome&Company, said, “In microbiome new drug development, securing a CDMO for rapid market launch and preemption will become important,” adding, “We will lead the global microbiome industry with a differentiated profit structure from existing bio companies.”

This content was produced with the assistance of AI translation services.